Cancer, Clinical Trials, and the Neighborhoods Left Behind
Education, transportation, and neighborhood resources had the greatest impact on cancer patients' ability to enroll in clinical trials.
Read Time: 4 minutes
Published:
Access to cancer care is not evenly distributed across the United States. Social determinants of health such as education, poverty, pollution, safety, and housing strongly impact patient outcomes and life expectancy.
Clinical trials can offer patients with cancer the opportunity to receive potentially life-prolonging treatment years before FDA approval. This is particularly important for patients with advanced disease whose standard treatment options have been exhausted. However, despite this promise, clinical trials are often available only at select institutions, and participation may require additional time, travel, and finances, creating barriers for many patients.
While national efforts have improved trial participation among different racial and ethnic groups, ages, and genders, many socially vulnerable patients are still underrepresented. For patients already facing barriers such as unreliable transportation or limited health literacy, enrolling in a trial can be daunting and, in some cases, unrealistic.
A critical challenge is that many of these social and economic barriers are not routinely captured in medical records. Without this information, it is difficult to identify which patients are being left out of clinical trials, making it harder to design and fund programs that could improve access to potentially life-prolonging novel therapies.
A patient’s neighborhood should not dictate access to potentially life-saving research. Yet too often, neighborhood barriers can determine whether clinical trials are truly within reach.
We studied adults in the United States who received treatment in 2022 and 2023 for the five cancers driving cancer-related death: lung, breast, prostate, colorectal, and pancreatic cancer. We searched the nationally representative Vizient database, which includes both academic and community hospitals, to identify patients enrolled in a clinical trial using trial-related insurance company billing codes. We then compared them to patients who did not participate in a trial. To better understand the role of community-level barriers, we used the Vizient Vulnerability Index, a health care-focused tool that measures social vulnerability at the census-tract level across nine categories of social determinants of health.
Where someone lives should not determine whether they can access cutting-edge cancer care.
We identified 2,660,566 patients,1.4% of whom enrolled in a clinical trial. We found that most clinical trial participants were young, White, privately insured, and had metastatic cancer. Patients living in vulnerable neighborhoods were least likely to enroll in cancer clinical trials. Education, transportation, and access to neighborhood resources had the biggest impact on clinical trial enrollment.
We also examined the interaction between social vulnerability and race in relation to clinical trial enrollment. When Black and White patients were both living in the most vulnerable neighborhood, Black patients were half as likely to enroll in a trial. In other words, high social vulnerability had a greater impact on Black patients’ ability to enroll in trials when compared to White patients.
Our study was one of the first to assess the relationship between social determinants of health and cancer clinical trial enrollment on a national scale. It helped identify specific barriers that future programs can address to make clinical trials more accessible to disadvantaged patients.
Patients from socially vulnerable communities, especially Black patients living in neighborhoods with fewer resources, remain underrepresented in cancer clinical trials. Identifying these neighborhoods and focusing our efforts on supporting residents can help us move from simply recognizing disparities to designing solutions that bring clinical trials and high-quality cancer care closer to the communities most often left behind.
One step would be encouraging clinical trial sponsors to cover the cost of trial-related travel and lodging to help to reduce out-of-pocket expenses for patients. The Clinical Trial Modernization Act (H.R.3521), a bipartisan bill introduced to the House of Representatives in 2025, would make it easier for clinical trial sponsors to help patients pay for the costs of participating in a trial, including transportation, meals, and certain medical expenses, without violating federal laws that restrict financial payments in health care. This bill would also indirectly support community outreach and use of digital tools that make remote participation easier for patients, reducing financial and geographic barriers to clinical trials. Where someone lives should not determine whether they can access cutting-edge cancer care.